Investigation of the impact of Sarizotan on the pharmacokinetics of levodopa

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 7, 2007, Pages 339-347

  Krösser, Sonja ^a   Neugebauer, Roland ^a   Chassard, Didier ^b   Kovar, Andreas ^a  

^a MERCK KGAA   (Germany)

^b Aster Cephac   (France)

Author keywords

Drug drug interactions; Levodopa; Sarizotan

Indexed keywords

BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; DOPA DECARBOXYLASE INHIBITOR; LEVODOPA; SARIZOTAN;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DIZZINESS; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE;

ADULT; CROSS-OVER STUDIES; DRUG INTERACTIONS; HUMANS; LEVODOPA; MALE; ORGANIC CHEMICALS;

EID: 35648982930     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.558     Document Type: Article

References (20)

1. Bartoszyk GD, Van Amsterdam C, Greiner HE et al. Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile. J Neural Transm 2004; 111: 113-126.
2. Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001; 57:1829-1834.
3. Rosengarten H, Bartoszyk GD, Quartermain D et al. The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 273-279.
4. Olanow CW, Damier P, Goetz CG et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 2004; 27: 58-62.
5. Krösser S, Tillner J, Fluck M, Ungethüm W, Wolna P, Kovar A. Pharmacokinetics of sarizotan after oral administration of single and repeat doses in healthy subjects. International Journal Clinical Pharmacology and Therapeutics 2007; 45(5): 271-280.
6. Nutt JG, Wooten GF. Diagnosis and initial management of Parkinson's disease. N Engl J Med 2005; 353: 1021-1027.
7. Koller WC. Levodopa in treatment of Parkinson's disease. Neurology 2000; 55: S2-S7.
8. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002; 41: 261-309.
9. Okereke CS. Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson's disease patients experiencing motor fluctuations with levodopa. J Pharm Pharm Sci 2002; 5: 146-161.
10. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001; 2: 577-588.
11. Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 2004; 62: S47-S55.
12. Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology 2004; 62: S56-S63.
13. Cedarbaum JM. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 1987; 13: 141-168.
14. Dingemanse J, Kleinbloesem CH, Zurcher G et al. Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics. Br J Clin Pharmacol 1997; 44: 41-48.
15. Robertson DR, Wood ND, Everest H et al. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol 1989; 28: 61-69.
16. Titus DC, August TF, Yeh KC et al. Simultaneous high-performance liquid chromatographic analysis of carbdopa, levodopa and 3-0-methyldopa in plasma and carbidopa, levodopa and dopamine in urine using electrochemical detection. J Chromatogr 1990; 534: 87-100.
17. Lutfullin A, Kuhlmann J, Wensing G. Adverse events in volunteers participating in phase I clinical trials: a single-center five-year survey in 1559 subjects. Int J Clin Pharmacol Ther 2005; 43: 217-226.
18. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: In Vivo Drug metabolism/Drug Interaction Studies - Study Design, Data Analysis, and Recommendations for Dosing and Labeling. 1998.
19. Goetze O, Wieczorek J, Mueller T et al. Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test. Neurosci Lett 2005; 375: 170-173.
20. Woitalla D, Goetze O, Kim JI et al. Levodopa availability improves with progression of Parkinson's disease. J Neurol 2006; 253: 1221-1226.